Psychopharmacology

Explore the unique mood-stabilizing properties of antiepileptics like lamotrigine, valproic acid, and carbamazepine in bipolar disorder treatment.

A clinical trial reveals challenges in assessing schizophrenia symptoms due to cultural and language differences, highlighting the need for improved measurement tools.

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.

Discover groundbreaking findings on digital therapeutics and medications for schizophrenia and depression, showcasing safety and efficacy in recent studies.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.

Vistagen's fasedienol fails to show significant efficacy in treating social anxiety disorder, despite favorable safety data from the PALISADE-3 trial.

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

New research suggests semaglutide may protect against lithium-induced renal injury, offering hope for safer bipolar disorder treatments.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

Adolescent cannabis use surges in Oklahoma, raising public health concerns amid rising THC potency and permissive regulations.

Read discussion of bromism, with case studies and background on bromine.

Lithium significantly reduces suicidal ideation and attempts in bipolar and major depressive disorder patients, enhancing long-term treatment outcomes.

Experts discuss the advantages of long-acting injectables in schizophrenia treatment, highlighting improved adherence, reduced relapse risk, and better patient outcomes.

Explore the complexities of treatment-resistant depression and the vital role of advanced practice providers in enhancing patient care and outcomes.

Take a look at the long-term effects of stimulant medications on ADHD, specifically tolerance and its implications for treatment efficacy.

Learn more about the prevalence and implications of psychotropic polypharmacy in treatment-resistant schizophrenia.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.